The Use of Rheumatic Disease Comorbidity Index for Predicting Clinical Response and Retention Rate in a Cohort of Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Alpha Inhibitors
Table 3
The role of RDCI and other baseline factors as predictors of 12-month EULAR good/moderate response and remission or low disease activity.
EULAR good/moderate response
Remission
Low disease activity
OR
95CI
P
OR
95CI
P
OR
95CI
P
Age, years
0.992
0.972-1.012
0.435
0.975
0.954-0.997
0.027
1.001
0.972-1.030
0.954
Sex
0.404
0.211-0.776
0.006
0.460
0.245-0.862
0.015
0.512
0.240-1.094
0.084
Disease duration, years
0.992
0.966-1.019
0.553
0.986
0.956-1.018
0.387
1.017
0.980-1.055
0.364
DAS28-ESR
1.540
1.191-1.990
0.001
0.541
0.404-0.724
<0.0001
0.955
0.674-1.351
0.793
HAQ
1.013
0.582-1.762
0.965
1.200
0.654-2.200
0.557
0.954
0.448-2.031
0.903
RF
1.749
0.982-3.114
0.058
1.739
0.988-3.063
0.055
1.055
0.489-2.278
0.891
Concomitant MTX
0.561
0.351-0.897
0.016
0.631
0.374-1.062
0.083
0.717
0.365-1.410
0.335
bDMARD (ETN vs ADA)
2.523
1.569-4.056
<0.001
1.623
0.966-2.729
0.067
1.557
0.792-3.062
0.199
RDCI
0.746
0.580-0.960
0.022
0.776
0.579-1.040
0.090
1.016
0.719-1.434
0.930
ADA: Adalimumab; DAS28-ESR: Disease Activity Score 28-Erythrocyte Sedimentation Rate; ETN: Etanercept; EULAR: European League Against Rheumatism; HAQ: Health Assessment Questionnaire; MTX: Methotrexate; OR: Odds Ratio; RDCI: Rheumatic Disease Comorbidity Index; RF: Rheumatoid Factor.
